Cargando…
Antithrombotics in heart failure
Heart failure is a common clinical condition associated with high morbidity and mortality rate despite significant improvements in pharmacotherapy and implementation of medical procedures. Patients with heart failure are at an increased risk of developing arterial and venous thrombosis, which contri...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Croatian Medical Schools
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295078/ https://www.ncbi.nlm.nih.gov/pubmed/25559833 http://dx.doi.org/10.3325/cmj.2014.55.621 |
_version_ | 1782352788365246464 |
---|---|
author | Miličić, Davor Samardžić, Jure Petričević, Mate |
author_facet | Miličić, Davor Samardžić, Jure Petričević, Mate |
author_sort | Miličić, Davor |
collection | PubMed |
description | Heart failure is a common clinical condition associated with high morbidity and mortality rate despite significant improvements in pharmacotherapy and implementation of medical procedures. Patients with heart failure are at an increased risk of developing arterial and venous thrombosis, which contribute to the high rate of adverse events and fatal outcomes. Many heart failure patients routinely receive antithrombotic therapy due to the presence of a specific indication for its use, like ischemic heart disease or atrial fibrillation. However, there is no solid evidence to support the routine use of antithrombotic agents in all heart failure patients. This article reviews the evidence for using antithrombotic therapy in heart failure patients. |
format | Online Article Text |
id | pubmed-4295078 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Croatian Medical Schools |
record_format | MEDLINE/PubMed |
spelling | pubmed-42950782015-01-21 Antithrombotics in heart failure Miličić, Davor Samardžić, Jure Petričević, Mate Croat Med J Advanced Heart Failure Heart failure is a common clinical condition associated with high morbidity and mortality rate despite significant improvements in pharmacotherapy and implementation of medical procedures. Patients with heart failure are at an increased risk of developing arterial and venous thrombosis, which contribute to the high rate of adverse events and fatal outcomes. Many heart failure patients routinely receive antithrombotic therapy due to the presence of a specific indication for its use, like ischemic heart disease or atrial fibrillation. However, there is no solid evidence to support the routine use of antithrombotic agents in all heart failure patients. This article reviews the evidence for using antithrombotic therapy in heart failure patients. Croatian Medical Schools 2014-12 /pmc/articles/PMC4295078/ /pubmed/25559833 http://dx.doi.org/10.3325/cmj.2014.55.621 Text en Copyright © 2014 by the Croatian Medical Journal. All rights reserved. http://creativecommons.org/licenses/by/2.5/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Advanced Heart Failure Miličić, Davor Samardžić, Jure Petričević, Mate Antithrombotics in heart failure |
title | Antithrombotics in heart failure |
title_full | Antithrombotics in heart failure |
title_fullStr | Antithrombotics in heart failure |
title_full_unstemmed | Antithrombotics in heart failure |
title_short | Antithrombotics in heart failure |
title_sort | antithrombotics in heart failure |
topic | Advanced Heart Failure |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295078/ https://www.ncbi.nlm.nih.gov/pubmed/25559833 http://dx.doi.org/10.3325/cmj.2014.55.621 |
work_keys_str_mv | AT milicicdavor antithromboticsinheartfailure AT samardzicjure antithromboticsinheartfailure AT petricevicmate antithromboticsinheartfailure |